Novonesis brings MicroBioGen into group to expand industrial yeast and biosolutions expertise

Posted on 2, October 2026 by | This entry was posted in Business, Denmark, Investment, Pharma & Biotech and tagged , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

The completed acquisition adds Australian yeast-breeding capabilities to Novonesis following more than a decade of collaboration and a 23% ownership stake

Novonesis and MicroBioGen logos displayed side by side

Novonesis completes its acquisition of MicroBioGen, strengthening its industrial yeast and biosolutions capabilities.

Novonesis has completed its acquisition of Australian biotechnology company MicroBioGen after obtaining all required regulatory approvals. The transaction builds on a collaboration dating back more than a decade and adds advanced yeast-breeding expertise that Novonesis says can support biosolutions development in bioethanol and other industries.

  • Novonesis has completed its acquisition of Australian biotechnology company MicroBioGen after receiving all required regulatory approvals.
  • The transaction builds on Novonesis' 2013 investment and existing 23% ownership stake in MicroBioGen.
  • MicroBioGen contributes advanced yeast-breeding expertise with a proven track record in bioethanol and potential applications across other industries served by Novonesis.
  • Novonesis says it will continue supporting MicroBioGen's existing partners and maintain continuity in current collaborations.
  • What company has Novonesis acquired?

    Novonesis has completed its acquisition of MicroBioGen, an Australian biotechnology company with expertise in yeast strains for industrial applications and a proven track record in bioethanol.

  • What was Novonesis’ relationship with MicroBioGen before the acquisition?

    Novonesis invested in MicroBioGen in 2013 and held an existing 23% ownership stake, with the companies collaborating for more than a decade.

  • What capabilities does MicroBioGen add to Novonesis?

    MicroBioGen adds advanced yeast-breeding expertise that complements Novonesis’ microbiology and industrial fermentation capabilities, with potential applications in bioethanol and other industries.

  • What will happen to MicroBioGen’s existing partnerships?

    Novonesis says it will continue to support MicroBioGen’s existing partners and ensure continuity in its collaborations.

(PRESS RELEASE) COPENHAGEN, Denmark, 2-Oct-2026 — /EuropaWire/ — Novonesis has completed its acquisition of MicroBioGen, an Australian biotechnology company with scientific expertise in yeast strains for industrial applications and a proven track record in bioethanol. All regulatory approvals have been obtained and the transaction has closed.

The acquisition builds on Novonesis’ investment in MicroBioGen in 2013 and its existing 23% ownership stake, further developing a collaboration that has extended for more than a decade.

“With this acquisition, we strengthen our yeast and R&D expertise and take another step toward delivering on our 2030 strategy. We are pleased to welcome our new colleagues to Novonesis and bring these capabilities into our company, where we can unlock its broader potential. The acquisition reflects our disciplined approach to investing for growth,”

said Ester Baiget, CEO of Novonesis.

As a pure-play biology company, Novonesis draws on expertise in microbiology and industrial fermentation. MicroBioGen’s advanced yeast-breeding capabilities complement that scientific foundation, creating opportunities to develop new biosolutions for customers across multiple industries.

“MicroBioGen has been a highly valued partner for more than a decade, and today marks the next step in that journey. By bringing together our complementary expertise and technologies, we can further strengthen our yeast capabilities and continue developing the biosolutions our customers need. We see potential for applications not only in bioethanol but also across other industries we serve, as is the case with many of our technologies,”

said Claus Crone Fuglsang, Chief Scientific Officer at Novonesis.

Novonesis will continue to support MicroBioGen’s existing partners and ensure continuity in its collaborations.

Media relations

Benjamin Hjorth
Senior Press Manager
media-relations@novonesis.com
+45 30 77 13 12

SOURCE: Novonesis

RELATED:
EDITOR'S PICK:

Comments are closed.